Introduction
• Patients with mild stroke/transient ischaemic attack (TIA) are at high risk of recurrent events.
• The Assessment of Real-world Evidence in Stroke/TIA (ARES) programme aims to characterize the management and outcomes of patients with mild stroke/TIA in real-world clinical practice in multiple countries around the world.
• Development of the ARES programme requires identification of suitable data sources that can provide consistent and/or complementary information in different countries and settings.
Conclusions
• Seven complementary data sources, from six countries, were identified for the ARES programme using the SURE methodology with input from principal investigators. • The ARES programme will provide observational data from contemporary populations with mild stroke/TIA in real-world clinical practice. • Studies will be reported individually owing to differences in the nature of the data sources. Data source characteristics were catalogued ('extracted') and evaluated for quality, suitability and accessibility. For databases, data owners were contacted ('queried') directly by e-mail and telephone, multiple times if necessary.
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Development of an international observational study programme to describe the management and outcomes of mild stroke and transient ischaemic attack in routine clinical practice suitable data sources (cohorts, registries and databases) were identified and characterized by systematic literature and web searches, supplemented with e-mail and telephone contact (Figure 1 ).
• Data sources were recommended if they:
- 
Results
• More than 2900 publications and 300 websites were screened, and 16 registries, 17 cohort studies and 43 databases were evaluated (Figure 2 ). • Nine data sources from seven countries were recommended, with seven complementary sources from six countries being included (Table 1 ).
• Based on a globally agreed study design concept, study protocols for each data source were developed locally and are currently being implemented.
• The ARES programme target population will be patients with mild ischaemic stroke (NIHSS score ≤5) or high-risk TIA (ABCD
